Orca Therapeutics B.V.   Report issue

For profit Phase 2
Founded: Nijmegen Netherlands (2005)

Organization Overview

First Clinical Trial
2019
NCT04097002
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Orca Therapeutics B.V.

Active Ingredients

Drugs in Phase 2 Trials (1)

orca-010 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1